Gliclazide MR versus glyburide for management of type 2 diabetes: a review of the clinical effectiveness and safety
Pohar R, Nkansah E
Record ID 32011001287
English
Authors' recommendations:
This report included studies in which the clinical effectiveness of a particular dosage form of gliclazide (gliclazide MR) was compared to glyburide. Based on data from one small study of relatively short duration, it appeared that adherence to therapy with 60 mg of gliclazide MR administered once daily may be superior to 5mg of glyburide administered twice daily and that this may be associated with better glycemic control. Safety, the risk hypoglycemia in particular, is also an important consideration in choosing drug therapy in type 2 diabetes. No conclusions about the relative safety of gliclazide MR and glyburide could be drawn from the included literature.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Diabetes Mellitus, Type 2
- Gliclazide
- Hypoglycemic Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.